| Přispěvatelé: |
F., Guerrini, Izzo, Barbara, E., Gottardi, M. T., Bochicchio, R., Morganti, S., Grassi, C., Baratè, S., Erricchiello, R., Pedri, M. R., Metelli, R., Lorenzatti, A., Di Vita, C., Domenichini, G., Saglio, Pane, Fabrizio, M., Petrini, G., Martinelli, S., Galimberti |
| Popis: |
Background: The chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome and the BCR-ABL1 fusion gene. The introduction of tyrosine kinase inhibitors (TKIs) significantly improved the survival, but 15% of patients don’t reach the optimal responses at the defined end-points or develop secondary resistance. The 2013 ELN guidelines identified as fundamental the early molecular response (BCR-ABL1/ABL1 % ≤10% IS), the MR3 (10% to the 0% (MR4, MR4.5, MR5) the two techniques have been compared in the different molecular subgroups. Results: Firstly we compared the number of detected ABL1 copies, that are fundamental for definition of the molecular response categories, especially for defining the degree of deep response (32,000 for MR4.5, 100,000 for MR5). By the “LabNet” method, 51 (81%) samples exceeded the 100,000 copies of ABL1, while by the automated method 81 samples (94.2%) reached >100,000 ABL1 copies. Then, we compared the two methods in discriminating positive and negative samples (K Cohen=0.690; p |
